Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 11.8% in the first quarter, according to its most recent filing with the SEC. The fund owned 105,879 shares of the biopharmaceutical company's stock after acquiring an additional 11,181 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.08% of Alnylam Pharmaceuticals worth $28,589,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. Capital World Investors raised its holdings in shares of Alnylam Pharmaceuticals by 0.6% during the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock valued at $3,906,284,000 after purchasing an additional 92,101 shares during the last quarter. Vanguard Group Inc. grew its position in Alnylam Pharmaceuticals by 2.5% during the first quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock valued at $3,525,544,000 after buying an additional 323,206 shares during the period. Capital Research Global Investors boosted its position in shares of Alnylam Pharmaceuticals by 32.9% in the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock worth $1,639,767,000 after purchasing an additional 1,724,610 shares during the period. T. Rowe Price Investment Management Inc. boosted its position in shares of Alnylam Pharmaceuticals by 39.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after purchasing an additional 1,245,195 shares during the period. Finally, Northern Trust Corp boosted its position in shares of Alnylam Pharmaceuticals by 19.6% in the fourth quarter. Northern Trust Corp now owns 878,860 shares of the biopharmaceutical company's stock worth $206,805,000 after purchasing an additional 143,941 shares during the period. Hedge funds and other institutional investors own 92.97% of the company's stock.

Analyst Upgrades and Downgrades

ALNY has been the topic of several recent analyst reports. Morgan Stanley increased their target price on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st. Wells Fargo & Company upped their price objective on shares of Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an "equal weight" rating in a report on Friday, August 1st. Jefferies Financial Group upped their price objective on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a "buy" rating in a research report on Monday, July 7th. Barclays boosted their price target on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an "overweight" rating in a research note on Friday, August 1st. Finally, Wolfe Research raised shares of Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a report on Monday, August 4th. Four investment analysts have rated the stock with a hold rating, twenty-three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $403.92.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 31,640 shares of the stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the completion of the sale, the chief executive officer owned 48,948 shares of the company's stock, valued at approximately $14,899,281.72. This represents a 39.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Trading Up 2.4%

Shares of NASDAQ ALNY traded up $10.28 on Thursday, reaching $442.80. 1,136,458 shares of the company traded hands, compared to its average volume of 951,044. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $445.20. The company has a 50 day moving average of $339.44 and a 200 day moving average of $287.99. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The stock has a market capitalization of $58.04 billion, a PE ratio of -179.27 and a beta of 0.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company had revenue of $773,689 billion during the quarter, compared to the consensus estimate of $633.54 million. During the same quarter in the prior year, the company posted ($0.13) EPS. The company's quarterly revenue was up 17.3% compared to the same quarter last year. On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.